by Dr. Ed Weber | Jul 16, 2019 | PCa Commentary
Managing PSA Recurrence Following Primary Radiation Therapy: Evolving Regimens for Focal Treatment Biochemical recurrence following primary irradiation is relatively common. “A recent series of 2694 patients treated with doses above 78 Gy revealed 10-year... by Dr. Ed Weber | May 10, 2019 | PCa Commentary
Radioligand therapy (RLT) – i.e. PSMA directed endoradiation with Lutetium-177 – has been developed to the extent that it is a realistic option for men with late stage, heavily pretreated metastatic castration-resistant prostate cancer. The national... by Dr. Ed Weber | Apr 11, 2019 | PCa Commentary
The commonly cited goal of ‘personalized medicine’ in regards to treatment selection based on genomic testing is early in the ‘work in progress’ stage. Breathtaking advances in next generation sequencing are very promising, but currently there are only limited options... by Dr. Ed Weber | Mar 13, 2019 | PCa Commentary
Ever since the first orchiectomy for metastatic prostate cancer in 1941 researchers and clinicians have been determinedly trying to restrain the androgen receptor (AR) by manipulating its hormone environment. But this wily adversary, like Houdini, after initial... by Dr. Ed Weber | Feb 7, 2019 | PCa Commentary
Enzalutamide (ENZ) was reviewed in the PCa Commentary of March/April 2014. Many important developments have taken place since then. This Commentary will discuss the current indications for ENZ and new studies of ENZ as monotherapy. A subsequent Commentary will address... by Dr. Ed Weber | Feb 6, 2019 | PCa Commentary
This Commentary benefitted from a review and suggestions from Thomas Hope, MD, Associate Professor of Abdominal Imaging and Nuclear Medicine, UCSF THE FIRST QUESTION likely, is why present a Commentary about the Gallium68-PSMA-11 PET/CT scan. Its...